We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App





`Immune Cop` Identified in Human Lungs That Detects SARS-CoV-2 Could Help Develop New COVID-19 Treatments

By HospiMedica International staff writers
Posted on 14 Jan 2021
Print article
Illustration
Illustration
Scientists have identified the sensor in human lungs that detects SARS-CoV-2 and signals that it is time to mount an antiviral response, providing insights into the molecular basis of severe disease that may enable new strategies for the treatment and prevention of COVID-19.

The new study by scientists at Sanford Burnham Prebys Medical Discovery Institute (La Jolla, CA, USA) surveyed 16 viral RNA binding proteins in human lung epithelial cells and identified MDA-5 as the predominant sensor responsible for activating interferon. MDA-5 detects double-stranded viral RNA—a form that the SARS-CoV-2 virus takes when it replicates to spread the infection. Prior to this research, it was known that activating interferon is key to a coordinated immune response to the virus, but the sentinel switch that controls the process was unknown.

“Our research has shown that MDA-5 is the immune cop that’s tasked to keep an eye out for SARS-CoV-2 and call for back-up,” said Sumit Chanda, Ph.D., director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and senior author of the study. “MDA-5 recognizes replicating viruses in lung cells and activates interferon, the body’s own frontline defender against viral invasion. Without a proper interferon response, viral infections can lead to deadly, out-of-control inflammatory reactions.”

“SARS-CoV-2 appears to disable the innate immune arm of our surveillance system, which, in the case of SARS-CoV-2 is controlled by MDA-5, and prevents the activation of interferon,” explained Chanda. “It’s the interferon response that drives the subsequent activation of many genes that exert antiviral activities—and data suggests that we need this activity to control early stages of viral infection and avoid the worst outcomes of COVID-19.”

“It’s possible that patients who become critically ill are deficient in the interferon signaling pathway,” added Chanda. “This research opens new avenues toward therapies that enhance the MDA-5 signaling to boost interferon levels early in infection to prevent severe disease. It also creates opportunities to develop COVID-19 vaccines that include an adjuvant(s) to enhance MDA-5 signaling. These would be formulations that use less ‘vaccine’ to minimize toxicity and side effects.”

Related Links:
Sanford Burnham Prebys Medical Discovery Institute


Print article

Channels

Business

view channel
Illustration

Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment

Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million. The acquisition of BardyDx,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.